Claritev Plunges on Disappointing 2026 Outlook

Dow Jones
02/25

By Elias Schisgall

 

Claritev shares plunged after the company's 2026 outlook for revenue and adjusted earnings disappointed Wall Street investors.

Shares fell 37% to $14.67 in midday Tuesday trading. The stock has fallen 80% over the past six months.

The healthcare technology company on Monday reported a loss of $80.6 million, or $4.88 a share, compared with a loss of about $138 million, or $8.53 a share, in the year-ago period.

Revenue rose to $246.6 million, up from $232.1 million a year prior. Analysts were expecting $241 million in revenue.

For the current year, the company said it expects revenue between $980 million and $1 billion and adjusted earnings before interest, taxes, depreciation, and amortization of between $605 million and $615 million.

Analysts were expecting revenue of $996.1 million and adjusted Ebitda of $620.8 million as of late January, prior to the earnings release.

 

Write to Elias Schisgall at elias.schisgall@wsj.com

 

(END) Dow Jones Newswires

February 24, 2026 11:51 ET (16:51 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10